Tixagevimab and Cilgavimab: Can we see More Recommendations for Monoclonal Antibodies Beyond COVID-19 Vaccination

Abstract

Nearly 3 years after its detection, the coronavirus disease 2019 (COVID-19) which is caused by severe acute respiratory syndrome CoV-2, is still a life-threatening global pandemic that has contributed to a high progression and mortality rate across the globe. This imposes the need for scientific research efforts in order to hold intense interest directed towards such exploration, for the development and optimization of different interventions to the COVID-19 infection. This commentary summarizes the potential clinical benefits for the recently authorized immunotherapy combination of Tixagevimab and Cilgavimab monoclonal antibodies for the prevention and treatment of COVID-19.